Get the Stockscreener App
11.58
4.99%
-0.5268
Anavex Life Sciences Corporation stock is traded at $11.58, with a volume of 1.41M.
It is down -4.99% in the last 24 hours and up +21.63% over the past month.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
See More
Previous Close:
$12.11
Open:
$11.91
24h Volume:
1.41M
Relative Volume:
0.98
Market Cap:
$978.54M
Revenue:
-
Net Income/Loss:
$-43.16M
P/E Ratio:
-17.55
EPS:
-0.66
Net Cash Flow:
$-29.31M
1W Performance:
+2.92%
1M Performance:
+21.63%
6M Performance:
+172.65%
1Y Performance:
+23.59%
1-Day Range:
$11.18
$12.35
1-Week Range:
$10.77
$14.44
52-Week Range:
$3.25
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
Name
Anavex Life Sciences Corporation
Sector
Industry
Phone
844-689-3939
Address
630 5TH AVENUE, NEW YORK
Compare AVXL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
11.59 | 978.54M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
402.01 | 103.35B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.82 | 77.35B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
622.74 | 37.04B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.59 | 30.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.81 | 26.97B | 3.30B | -501.07M | 1.03B | -2.1146 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Sep-23-21 | Initiated | BTIG Research | Buy |
| Dec-16-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-28-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-27-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-18-19 | Initiated | Janney | Buy |
| May-16-18 | Resumed | Maxim Group | Buy |
| Mar-08-18 | Initiated | ROTH Capital | Buy |
| Feb-13-18 | Reiterated | Maxim Group | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Feb-07-17 | Initiated | Noble Financial | Buy |
| Mar-29-16 | Initiated | FBR Capital | Outperform |
View All
Anavex Life Sciences Corporation Stock (AVXL) Latest News
HC Wainwright Has Optimistic Outlook of AVXL Q1 Earnings - Defense World
Anavex Life Sciences: Short-Squeeze Target Gains Traction - Investing.com
Anavex Life Sciences: Jumping In On Time Ahead Of An Early Alzheimer's Decision - Seeking Alpha
Anavex Life Sciences (NASDAQ:AVXL) Price Target Raised to $42.00 at HC Wainwright - Defense World
Anavex Life Sciences (NASDAQ:AVXL) vs. Autolus Therapeutics (NASDAQ:AUTL) Head-To-Head Analysis - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Trading Up 6.9% After Analyst Upgrade - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Shares Up 6.9% on Analyst Upgrade - MarketBeat
Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday - Benzinga
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Anavex Life Sciences Faces Manufacturing Challenges Impacting Product Launch and Financial Stability - Yahoo Finance
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow - Simply Wall St
State Street Corp Sells 674,409 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Sold by State Street Corp - MarketBeat
Fmr LLC Decreases Position in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Shares Gap Up After Earnings Beat - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Shares Gap Up After Strong Earnings - MarketBeat
Greenfire Resources, Hut 8, TeraWulf, MicroStrategy And Other Big Stocks Moving Higher On Tuesday - Benzinga
Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis (NASDAQ:AVXL) - Seeking Alpha
Anavex Life Sciences (NASDAQ:AVXL) Given “Buy” Rating at D. Boral Capital - Defense World
Anavex Life Sciences Corp (AVXL) Q4 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Anavex Life Sciences Corp (AVXL) Q4 2024 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Anavex Life Sciences (NASDAQ:AVXL) Reaches New 1-Year High After Earnings Beat - Defense World
Anavex Life Sciences Corp. (AVXL) reports earnings - Quartz
Anavex Life Sciences Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2024 - Marketscreener.com
Anavex Life Sciences: Fiscal Q4 Earnings Snapshot - The Washington Post
Anavex Life Sciences (NASDAQ:AVXL) Sets New 12-Month High on Earnings Beat - MarketBeat
Earnings call transcript: Anavex Life Sciences Q4 2024 beats EPS forecast - Investing.com Australia
Anavex Life Sciences (NASDAQ:AVXL) Receives "Buy" Rating from D. Boral Capital - MarketBeat
Anavex Life Sciences Corp. Reports Earnings Results for the Fourth Quarter Ended September 30, 2024 - Marketscreener.com
Anavex Life Sciences (NASDAQ:AVXL) Posts Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Anavex Life Sciences Reports $132M Cash Position, Advances Alzheimer's Drug Development - StockTitan
Dow Jumps Around 500 Points But Records 3rd Straight Weekly Loss: Greed Index Moves To 'Fear' Zone - Benzinga
Qualcomm, Limoneira And 3 Stocks To Watch Heading Into Monday - Benzinga
Anavex Life Sciences (NASDAQ:AVXL) vs. Aligos Therapeutics (NASDAQ:ALGS) Head to Head Analysis - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 8.5%Time to Buy? - MarketBeat
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 - The Manila Times
Anavex Life Sciences Sets Date for Q4 2024 Earnings Release and Strategic Update - StockTitan
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Shares Gap Up – Should You Buy? - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Shares Gap UpShould You Buy? - MarketBeat
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference - The Manila Times
Anavex to Unveil 4-Year Alzheimer's Drug Data at JPM Healthcare Conference - StockTitan
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 7.8% – Here’s What Happened - Defense World
Anavex Life Sciences (NASDAQ:AVXL) Stock Price Up 7.8%What's Next? - MarketBeat
Anavex Life Sciences (LTS:0HFR) EPS (Diluted) : $-0.51 (TTM As of Jun. 2024) - GuruFocus.com
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 - The Manila Times
Anavex Life Sciences to Present at Major Evercore ISI Healthcare Conference - StockTitan
Anavex Life Sciences (NASDAQ:AVXL) Trading 8.1% HigherShould You Buy? - MarketBeat
Anavex Stock Jumps Pre-Market After Submitting Oral Alzheimer's Drug To European Regulators For Approval: Retail Over The Moon - MSN
Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from HC Wainwright - MarketBeat
Anavex Life Sciences (NASDAQ:AVXL) Earns “Buy” Rating from D. Boral Capital - Defense World
Anavex Life Sciences Corporation Stock (AVXL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anavex Life Sciences Corporation Stock (AVXL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
May 15 '24 |
Buy |
4.52 |
5,000 |
22,600 |
5,000 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 28 '24 |
Option Exercise |
1.32 |
73,380 |
96,862 |
1,323,590 |
| MISSLING CHRISTOPHER U | President and CEO |
Mar 28 '24 |
Sale |
5.11 |
73,380 |
374,972 |
1,250,210 |
1.03%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):